EMMANUEL AKPORIAYE, PH.D.
Adjunct Scientist, Legacy Research Institute
Dr. Akporiaye received his PhD in Microbiology from the University of New Mexico, Albuquerque, and completed his post-doctoral training in cancer biology and immunology in the Life Sciences Division at The Los Alamos National Laboratory.
Dr. Akporiaye is the Founder and CEO of Veana Therapeutics Inc., a biotechnology company founded as a spin-off from the Earle A. Chiles Research Institute of the Providence Cancer Institute.
α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the anti-tumor immune response
The vitamin E analog alpha-TEA stimulates tumor autophagy and enhances antigen cross-presentation
Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy.
Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25-Foxp3+ T cells.
Dr. Akporiaye’s research is focused on understanding the interactions between cancer cells and immune cells that favour tumor growth and progression and developing novel therapies that are safe, effective, and less toxic while at the same time ensuring that the patient’s quality of life is not compromised. Dr. Akporiaye is a Fulbright Senior Scholar and has served on several national and regional Scientific Review Committees and Advisory Boards focused on cancer immunology and immunotherapy, including The National Institutes of Health, Susan Komen Race for the Cure Foundation, the DOD Breast Cancer Research Program, The Fred Hutchinson Cancer Research Center Ovarian Cancer SPORE and Legere Pharmaceuticals, Inc. He recently completed a 6-year rotation as a Permanent Member of the NIH Transition to Independence Initial Review Group for the advancement of basic and clinical scientists to independent careers.